A sequential Monte Carlo approach to derive sampling times and windows for population pharmacokinetic studies by McGree, James et al.
This is the author’s version of a work that was submitted/accepted for pub-
lication in the following source:
McGree, J.M., Drovandi, C.C., & Pettitt, A.N. (2012) A sequential Monte
Carlo approach to design for population pharmacokinetics studies. Journal
of Pharmacokinetics and Pharmacodynamics, 39(5), pp. 519-526.
This file was downloaded from: http://eprints.qut.edu.au/46540/
c© Copyright 2012 Springer
The original publication is available at SpringerLink
http://www.springerlink.com
Notice: Changes introduced as a result of publishing processes such as
copy-editing and formatting may not be reflected in this document. For a
definitive version of this work, please refer to the published source:
http://dx.doi.org/10.1007/s10928-012-9265-1
This is the author’s version of a work that was submitted/accepted for pub-
lication in the following source:
McGree, James, Drovandi, Christopher C., & Pettitt, Anthony N. (2011) A
sequential Monte Carlo approach to design for phase III clinical trials. A
SEQUENTIAL MONTE CARLO APPROACH TO DESIGN FOR PHASE III
CLINICAL TRIALS.
This file was downloaded from: http://eprints.qut.edu.au/47096/
c© Copyright 2011 The Authors
Notice: Changes introduced as a result of publishing processes such as
copy-editing and formatting may not be reflected in this document. For a
definitive version of this work, please refer to the published source:
Noname manuscript No.
(will be inserted by the editor)
A SEQUENTIAL MONTE CARLO APPROACH TO DESIGN
FOR PHASE III CLINICAL TRIALS
McGree, J.M. ⋅ Drovandi, C.C. ⋅ Pettitt, A.N.
Received: date / Accepted: date
Abstract Here we present a sequential Monte Carlo approach that can be used to find optimal
designs. Our focus is on the design of phase III clinical trials where the derivation of sampling
windows is required, along with the optimal sampling schedule. The search is conducted via a
particle filter which traverses a sequence of target distributions artificially constructed via an
annealed utility. The algorithm derives a catalog of highly efficient designs which, not only contain
the optimal, but can also be used to derive sampling windows. We demonstrate our approach by
designing a hypothetical phase III clinical trial.
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1 Introduction
Sequential Monte Carlo (SMC) algorithms are useful for sampling from a sequence of target distri-
butions that are in some sense connected (see [1]). A set of weighted samples (particles) is generated
from an easy-to-sample-from tractable distribution and the particles are propagated through the
sequence of targets via re-weighting, re-sampling and mutation steps. The eventual outcome is a
weighted sample from the target of interest.
In this paper, SMC methodology is applied to design phase III clinical trials. The primary
goal of these trials is to confirm the pharmacokinetics (PK) of the developmental drug generally
described by a nonlinear mixed effects model. Designing these trials requires selecting sampling
times; times at which to take plasma samples. These designs are typically static in that a fixed
design is used throughout the duration of the study with all patients sampled at similar times.
We propose finding the sampling times using SMC via an annealed utility, see [2, 3]. A sequence
of target distributions is constructed artificially by incrementally ‘powering up’ a utility function.
Iterating in this manner allows a smooth transition between target distributions to the eventual
optima. As will be discussed, a Metropolis-Hasting step, see [4, 5], is used to diversify the particle
set at certain stages in the algorithm. The sequence of target distributions also allows efficient
proposals (based on the previous target distribution) to be constructed, avoiding the need to tune
the algorithm.
Implementing SMC in this manner not only finds the optimal sampling times, but this particle
filter approach also yields a catalog of highly efficient designs. We propose using this catalog in
constructing sampling windows, a subset of the sampling interval in which efficient designs lie.
Sampling windows are of interest as they provide flexibility in collecting plasma samples while
maintaining a high level of efficiency in parameter estimates. This flexibility has been termed
‘planned sub-optimality’ by [6], and is preferred over ‘unplanned sub-optimality’ which can result
when specific sampling schedules are not followed. Hence, in finding the optimal design using this
approach based on SMC, we also obtain (for free) the sampling windows.
Sampling windows are generally difficult to find in the context of nonlinear mixed effects models,
and, in fact, no analytic solution generally exists for the derivation. Various methods have been
A SEQUENTIAL MONTE CARLO APPROACH TO DESIGN FOR PHASE III CLINICAL TRIALS 3
proposed in the literature. Work of interest includes [7, 8, 9]. Unfortunately, these approaches either
do not allow different sized windows and/or windows that are not symmetric around, say, the 퐷-
optimal sampling times. Such properties are desirable as they highlight the sensitivity/importance
of particular sampling times in yielding efficient estimates of parameters. Other work of interest is
by [10] who proposed deriving sampling windows based on the equivalence theorem of퐷-optimality.
However, this approach is generally not appropriate for the design of nonlinear mixed effects models.
A simulation-based approach to deriving sampling windows given by [6] provides desirables such
as different sized windows that need not be symmetric around the 퐷-optimal sampling times but
the approach is conditional on the 퐷-optimal design. Hence, the optimal design must first be found
before the approach can be applied.
The paper is outlined as follows. In Section 2, the algorithm used to locate sampling times is
outlined and the method for deriving sampling windows presented. In Section 3, the algorithm is
applied to design a hypothetical phase III clinical trial. The paper concludes with a discussion in
Section 4.
2 Sequential Monte Carlo algorithm - Annealed utility
The SMC algorithm used to find optimal sampling times and sampling windows is outlined in this
section. The approach is based on a particle filter to find maximum likelihood estimates in latent
variable models given by [11] and the SMC approach of [1].
The algorithm is based on a sequence of target distributions artificially constructed by ‘powering
up’ some measure of utility 푢(푿) for each particle 푿, see [3, 5, 12]. In our case, the particle 푿
represents a sampling schedule. The sequence of targets, 휋푡, is given by
휋푡 = 푝(푿푡)푢(푿푡)
훾푡 , 푡 = 0, . . . , 푇
where 푝(푿푡) is the prior distribution of 푿푡 and 훾0 < 훾1 < . . . < 훾푇 .
At the 푡th iteration of the algorithm, current progress of the search is given by the particle set
and corresponding particle weights denoted as {푿
(푘)
푡 ,푊
(푘)
푡 }
푁
푘=1. Between iterations, 훾푡 is increased
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incrementally to 훾푡+1. Given {푿
(푘)
푡 ,푊
(푘)
푡 }
푁
푘=1 is a discrete approximation of 휋푡, the particle weights
need to be adjusted such that the weighted particles now estimate 휋푡+1. This is the re-weight step
in the SMC algorithm, and in this annealed utility framework, is performed as follows:
푤
(푘)
푡+1 = 푊
(푘)
푡
휋푡+1(푿
(푘)
푡 )
휋푡(푿
(푘)
푡 )
, 푊
(푘)
푡+1 = 푤
(푘)
푡+1/
푁∑
푗=1
푤
(푗)
푡+1.
Hence, particles with relatively high utility are given more weight than those with relatively
small utility. This has the effect of placing more weight on promising particles in the search for
the optimal sampling times. As the 훾s increase, this has the effect of gradually steepening the
distribution helping to locate the global optima (mode/s). This is similar to simulated annealing,
see [13].
The choice of how to increment 훾푡 is important. If the increment is too large, then this could
lead to the majority of the particle weight only being on a few particles. This is not ideal as it
is preferred to have a diverse set of particles driving the optimization thereby hopefully providing
robustness against local optima. On the other hand, if the increment is too small, then the particle
set is not really moving anywhere, leading to computational inefficiency.
We propose choosing the increment, say, 훿푡 = 훾푡 − 훾푡−1 based on how efficient the re-weighted
particle sample from the target distribution will be. This efficiency can be measured by the effective
sample size (퐸푆푆) which indicates how ‘close’ the weighted sample is to a perfect, independent
draw from the target distribution. The 퐸푆푆 at target 푡 can be approximated as:
퐸푆푆 = 1/
푁∑
푘=1
(푊
(푘)
푡 )
2.
Hence, the increment is chosen to maintain a specified level of efficiency in the sample, say,
퐸, see line 8 of Algorithm 1. In fact, in an SMC framework, the 퐸푆푆 of a weighted sample from
a target should be checked after every re-weight step to ensure the particle set does not become
degenerate. To avoid this, re-sample and mutation steps should be used, and these are discussed
next.
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Given our choice of increment, once the particle set has been re-weighted, the 퐸푆푆 will be
undesirably small. To maintain an 퐸푆푆 near 푁 , we initially perform a re-sample step (line 12
of Algorithm 1). This has the effect of duplicating promising particles and deleting those with
relatively small weight. There are a number of re-sampling techniques available in the literature,
for example, multinomial, residual and systematic, see [14, 15]. In the examples that follow in the
next section, we use systematic re-sampling.
The final step in an iteration of this algorithm is to perform a mutation step (lines 13-15 of
Algorithm 1). This mutation step generates new particles from the current set which reflect the
current target distribution. This step was performed via an MCMC kernel. In our algorithm, we
used a random walk Metropolis-Hastings step to determine whether to accept or reject a proposal
for each component of a particle (component-wise update). The variance of the random walk (or
tuning parameter) was taken as the variance of each element in the particle set (self-tuning). Given
each element of a particle is exchangeable, that is, 푢(푿) is invariant to the order of푿, each particle
was ordered before the variance was evaluated.
The algorithm will then continue to iterate until the stopping criterion is met. In this paper,
we continue until the variance of the utility of the particle set is sufficiently small.
Algorithm 1 General SMC procedure for utility annealing
1: for 푘 = 1 : 푁 do
2: Draw 푿
(푘)
0 ∼ 푝(푿) %%%% Draw from prior
3: Let 푊
(푘)
0 = 1/푁
4: end for
5: Let 훾0 = 0 and 푡 = 0
6: while VAR{푢(푿
(푘)
푡 )}
푁
푘=1 > 푡표푙 do
7: 푡 = 푡+ 1
8: 훿푡 =
argmin
훿 (퐸푆푆(훿)−푁퐸)2 %%%% Appropriate increment
9: 훾푡 = 훾푡−1 + 훿푡
10: 푤
(푘)
푡 = 푊
(푘)
푡−1휋푡(푿
(푘)
푡 )/휋푡−1(푿
(푘)
푡 ) %%%% Calculate importance weights
11: 푊
(푘)
푡 = 푤
(푘)
푡 /
∑푁
푗=1 푤
(푗)
푡 %%%% Normalise weights
12: Re-sample from {푿
(푘)
푡−1,푊
(푘)
푡 }
푁
푘=1 → {푿
(푘)
푡−1, 1/푁}
푁
푘=1
13: for 푘 = 1 : 푁 do
14: Move 푿
(푘)
푡 with MCMC kernel 휋푡(푿푡) of invariant distribution
15: end for
16: Set 푿푡 =푿푡−1
17: end while
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3 Example: Phase III clinical trial
Consider a phase III clinical trial where it is thought that the PK of the drug of interest can be
described by the following nonlinear mixed effects model, see [16]:
푦푖푗 =
퐷푘푎푖
푉푖(푘푎푖 − 퐶푙푖/푉푖)
(
exp
(
−
퐶푙푖
푉푖
푡푖푗
)
− exp (−푘푎푖푡푖푗)
)
(1 + 휖1푖푗) + 휖2푖푗 , (1)
for the 푗th measurement on individual 푖, for 푖 = 1, . . . , 25. Assume that all individuals receive
a single dose 퐷 = 100 and blood samples are to be collected on each patient at the same sampling
times. We are therefore required to find the optimal choice of these sampling times and provide
efficient sampling windows. Also assume that
log 휽푖 ∼ 푁
⎛
⎜⎜⎜⎜⎜⎜⎝
⎡
⎢⎢⎢⎢⎢⎢⎣
log(1)
log(4)
log(20)
⎤
⎥⎥⎥⎥⎥⎥⎦
,
⎡
⎢⎢⎢⎢⎢⎢⎣
0.25 0 0
0.1 0
0.1
⎤
⎥⎥⎥⎥⎥⎥⎦
⎞
⎟⎟⎟⎟⎟⎟⎠
,
where 휽푖 = [푘푎푖, 퐶푙푖, 푉푖]
′, 푡푗 ∈ [0, 24] represents the 푗th sampling time for all individuals,
푿 = [푡1, . . . , 푡푛푖 ], 휖1푖푗 ∼ 푁(0, 0.0225), 휖2푖푗 ∼ 푁(0, 0.01). All variance terms are to be estimated
with the exception of the additive residual variance which is considered a nuisance parameter. This
gives a total of seven parameters to be estimated.
In order to find the optimal sampling times and sampling windows, a utility is required. A
common choice for a utility function in the design literature for PK studies is the determinant
of the expected Fisher information. In general, there is no closed form solution for the expected
Fisher information for a nonlinear mixed effects model. [17] and [18] proposed approximating the
nonlinear model via a first-order Taylor series expansion around the random effects, and derive
Fisher information based on this approximation. We follow their methodology in the consideration
of 퐷-optimality as a measure of utility for the sampling schedule 푿.
Other settings for the algorithm were, 푁 = 1000, 퐸 = 0.75 and the elements of each particle
were drawn from independent uniform distributions on the interval [0, 24]. For the first example,
푡표푙 was set to 0.0003 and for the second example 푡표푙 = 0.0001.
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3.1 Three sampling times
The SMC algorithm was run to find the 퐷-optimal design to locate three sampling times. The
particle and utility values at iterations 1 to 10 of the algorithm are captured in Figures 1 and 2,
respectively. Initially in Figure 1 there is essentially no information about what sampling times may
be optimal. As the algorithm iterates, three peaks become apparent relating to the three sampling
times. Eventually these peaks become non-overlapping and well-defined. The corresponding utility
values are shown in Figure 2. As can be seen, there is a general movement towards maximizing
the utility. In fact, after six iterations, most particles/sampling schemes are rather efficient. The
퐷-optimal design found was:
푿
∗ = [0.28, 2.22, 12.64].
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Fig. 1 Density plots of particles at iterations 푡 = 1 to 10.
The density plot of particles when the algorithm stopped is shown in Figure 3. The plot shows
the catalog of designs that are available once the stopping criterion has been met. It seems as though
most flexibility (or planned sub-optimality) is available when collecting the third blood sample, with
the least flexibility being available when collecting the first blood sample. The sampling windows
were derived from this catalog by taking the 2.5th and 97.5th percentiles of each peak/distribution.
These were:
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Fig. 2 Density plots of utility values of particles at iterations 푡 = 1 to 10.
푿 ∈
⎡
⎢⎢⎣
0.28 2.28 10.05
0.73 4.06 15.46
⎤
⎥⎥⎦ .
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Fig. 3 Density of particles (sampling times) found when searching for the 퐷-optimal design with three sampling
times.
It is important to evaluate the sampling windows before implementation in practice to en-
sure an overall level of efficiency from designs randomly drawn from these windows. The windows
were evaluated by randomly sampling schedules uniformly from the sampling windows, and the
퐷-efficiency of these designs was computed (ratio of scaled determinants of expected Fisher infor-
mation given by the randomly drawn design and the 퐷-optimal design). The histogram of these
퐷-efficiencies is given in Figure 4. As can be seen, all designs randomly drawn from the windows
were highly 퐷-efficient with efficiencies greater than 0.95.
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Fig. 4 Evaluation of the sampling windows where the 퐷-optimal design contains three sampling times.
3.2 Five sampling times
Now suppose there is interest in obtaining a sampling schedule with five sampling times. The
퐷-optimal design found was:
푿
∗ = [0.36, 3.20, 3.57, 3.74, 11.88].
Figure 5 shows the distribution of sampling times when the algorithm stopped. Despite search-
ing for five sampling times, only three peaks appear. This suggests that efficient sampling windows
can be obtained by only considering three windows and taking multiple samples in one or more
windows. Given this and the 퐷-optimal design, we assume three sampling windows (instead of
five) are appropriate for this example and take 3 samples from the second window. As in the first
example, the most flexibility in the sampling schedule is available when collecting the third blood
sample.
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  X  
D
en
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ty
Fig. 5 Density of particles (sampling times) found when searching for the 퐷-optimal design with five sampling
times.
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The following sampling windows were found again by taking the 2.5th and 97.5th percentiles
of the peaks/distributions shown in Figure 5.
푿 ∈
⎡
⎢⎢⎣
0.25 2.67 11.96
0.61 4.75 15.67
⎤
⎥⎥⎦ .
Again, these windows were evaluated in a similar manner to before, with the exception of taking
three samples in the second window. Figure 6 shows that all of the 퐷-efficiencies for each randomly
drawn design were high, with all being larger than 0.96.
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Fig. 6 Evaluation of the sampling windows where the 퐷-optimal design contains five sampling times.
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4 Conclusion
In this paper, we have presented a novel algorithm based on SMC for finding sampling schedules
in PK studies. The advantage of the algorithm is that sampling windows are also given once the
optimal design has been located. The sampling windows were shown to have desirable properties
such as different sizes for different sampling times and also allowed windows to be derived in the
case of an optimal sampling schedule having many sampling times.
The main disadvantage of the approach is that one cannot directly specify the minimum 퐷-
efficiency of a design resulting from the sampling windows. Some control can be achieved through
the choice of stopping rule, however, this may be a difficult choice in practice. We considered
stopping the algorithm once the variance of the utilities given by the particles was smaller than
a pre-specified tolerance level 푡표푙. If 푡표푙 were too small, then this would result in little flexibility
around the 퐷-optimal sampling times. Indeed, slightly ‘tighter’ sampling windows resulted in the
second example where 푡표푙 was the smallest. On the other hand, if 푡표푙 were too large, then one may
be concerned that a sub-optimal design was found. Inflated 퐷-efficiencies would result.
Sampling windows can provide some robustness to model and parameter misspecification. How-
ever, extensions of our approach could incorporate such uncertainty. This would require evaluating
the expectation of the utility over the model and parameter uncertainty. Typically, this will be
a multi-dimensional integral with no closed form solution. The expectation of the utility could
be approximated, for example, via Monte Carlo integration. Alternatively, other utilities could be
considered to incorporate such uncertainty, see [19].
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